Micah Benson

Company: KSQ Therapeutics

Job title: Chief Scientific Officer

Seminars:

eTILÒ & eCARÒ Therapies: CRISPR/Cas9 Engineered T-Cells to Treat Solid Tumors 9:00 am

CRISPRomics discovery platform identified SOCS1 and Regnase-1 as top T-cell targets enhancing functionality Inactivation of SOCS1 and Regnase-1 enhances the activity of CRISPR/Cas9-engineered TIL (eTILÒ) against solid tumors Inactivation of SOCS1 and Regnase-1 enhances the activity of CRISPR/Cas9-engineered CARTs (eCARÒ) against solid tumorsRead more

day: Post-Conference Solid Tumor Focus Day